MX384905B - Degradadores de proteínas de bromodominio y dominioextraterminal (bet). - Google Patents
Degradadores de proteínas de bromodominio y dominioextraterminal (bet).Info
- Publication number
- MX384905B MX384905B MX2018012379A MX2018012379A MX384905B MX 384905 B MX384905 B MX 384905B MX 2018012379 A MX2018012379 A MX 2018012379A MX 2018012379 A MX2018012379 A MX 2018012379A MX 384905 B MX384905 B MX 384905B
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- bet
- bromodola
- extraterminal domain
- protein degraders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662321499P | 2016-04-12 | 2016-04-12 | |
| US201662393888P | 2016-09-13 | 2016-09-13 | |
| PCT/US2017/026278 WO2017180417A1 (en) | 2016-04-12 | 2017-04-06 | Bet protein degraders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018012379A MX2018012379A (es) | 2019-07-04 |
| MX384905B true MX384905B (es) | 2025-03-14 |
Family
ID=58548921
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018012379A MX384905B (es) | 2016-04-12 | 2017-04-06 | Degradadores de proteínas de bromodominio y dominioextraterminal (bet). |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10633386B2 (enExample) |
| EP (1) | EP3442976B1 (enExample) |
| JP (1) | JP7072519B2 (enExample) |
| KR (1) | KR20180132861A (enExample) |
| CN (1) | CN109311890B (enExample) |
| AU (1) | AU2017250076B2 (enExample) |
| BR (1) | BR112018070859A2 (enExample) |
| CA (1) | CA3020541A1 (enExample) |
| IL (1) | IL262139B (enExample) |
| MX (1) | MX384905B (enExample) |
| RU (1) | RU2752677C2 (enExample) |
| SG (1) | SG11201808729WA (enExample) |
| UA (1) | UA123168C2 (enExample) |
| WO (1) | WO2017180417A1 (enExample) |
| ZA (1) | ZA201806969B (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6968823B2 (ja) | 2016-04-22 | 2021-11-17 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | Ｅｇｆｒの分解のための二官能性分子、及び使用方法 |
| ES2989988T3 (es) | 2016-05-10 | 2024-11-28 | C4 Therapeutics Inc | Degronímeros heterorocíclicos para la degradación de proteínas diana |
| CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
| WO2017197051A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Amine-linked c3-glutarimide degronimers for target protein degradation |
| WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
| US11285218B2 (en) * | 2016-06-23 | 2022-03-29 | Dana-Farber Cancer Institute, Inc. | Degradation of bromodomain-containing protein 9 (BRD9) by conjugation of BRD9 inhibitors with E3 ligase ligand and methods of use |
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| CN109422751B (zh) * | 2017-09-03 | 2022-04-22 | 上海美志医药科技有限公司 | 一类具有降解酪氨酸蛋白激酶jak3活性的化合物 |
| CN111315735B (zh) | 2017-09-04 | 2024-03-08 | C4医药公司 | 二氢苯并咪唑酮 |
| CN111278816B (zh) | 2017-09-04 | 2024-03-15 | C4医药公司 | 二氢喹啉酮 |
| EP3679026A1 (en) | 2017-09-04 | 2020-07-15 | C4 Therapeutics, Inc. | Glutarimide |
| JP2021502388A (ja) * | 2017-11-10 | 2021-01-28 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | Ａｓｈ１ｌ阻害剤及びそれを用いた治療方法 |
| EP3710002A4 (en) | 2017-11-16 | 2021-07-07 | C4 Therapeutics, Inc. | DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION |
| CN111902141A (zh) | 2018-03-26 | 2020-11-06 | C4医药公司 | 用于ikaros降解的羟脑苷脂结合剂 |
| CN112312904B (zh) | 2018-04-16 | 2025-01-07 | C4医药公司 | 螺环化合物 |
| EP3578561A1 (en) | 2018-06-04 | 2019-12-11 | F. Hoffmann-La Roche AG | Spiro compounds |
| US11969472B2 (en) | 2018-08-22 | 2024-04-30 | Cullgen (Shanghai), Inc. | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use |
| IL280984B2 (en) | 2018-08-22 | 2025-02-01 | Cullgen Shanghai Inc | Tropomyosin receptor kinase (TRK) inhibitor compounds and methods of use |
| WO2020051235A1 (en) | 2018-09-04 | 2020-03-12 | C4 Therapeutics, Inc. | Compounds for the degradation of brd9 or mth1 |
| WO2020064002A1 (zh) * | 2018-09-30 | 2020-04-02 | 中国科学院上海药物研究所 | 异吲哚啉类化合物、其制备方法、药物组合物及用途 |
| WO2020076996A1 (en) * | 2018-10-09 | 2020-04-16 | The Regents Of The University Of California | Covalent targeting of e3 ligases |
| CN120698983A (zh) | 2018-12-20 | 2025-09-26 | C4医药公司 | 靶向蛋白降解 |
| US20220089589A1 (en) * | 2019-01-07 | 2022-03-24 | Dana-Farber Cancer Institute, Inc. | SMALL MOLECULE DEGRADERS OF FKBP12 VIA RECRUITMENT OF VON HIPPEL-LINDAU E3 UBIQUITIN LIGASE (VHL) E3 UBIQUITIN LIGASE, AND USES IN dTAG SYSTEMS |
| BR112021014220A2 (pt) * | 2019-01-22 | 2022-01-18 | Merck Patent Gmbh | Derivados heterocíclicos |
| WO2020181232A1 (en) | 2019-03-06 | 2020-09-10 | C4 Therapeutics, Inc. | Heterocyclic compounds for medical treatment |
| US12390532B2 (en) * | 2019-06-12 | 2025-08-19 | Shanghaitech University | ALK protein regulator and anti-tumor application thereof |
| WO2021065980A1 (ja) * | 2019-09-30 | 2021-04-08 | 協和キリン株式会社 | Ｂｅｔ分解剤 |
| WO2023205701A1 (en) | 2022-04-20 | 2023-10-26 | Kumquat Biosciences Inc. | Macrocyclic heterocycles and uses thereof |
| EP4110772A4 (en) | 2020-02-26 | 2024-04-03 | Cullgen (Shanghai), Inc. | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE |
| MX2022010952A (es) | 2020-03-05 | 2022-10-07 | C4 Therapeutics Inc | Compuestos para la degradacion dirigida de brd9. |
| CN113387932B (zh) * | 2020-03-14 | 2023-05-09 | 成都先导药物开发股份有限公司 | 一种诱导brd4蛋白降解的双功能化合物 |
| CN112920176B (zh) * | 2020-05-25 | 2022-11-04 | 四川大学华西医院 | 可诱导prc2蛋白复合物核心亚基降解的双功能化合物和药物组合物及应用 |
| JP2023538517A (ja) | 2020-08-05 | 2023-09-08 | シーフォー セラピューティクス， インコーポレイテッド | Ｒｅｔの標的分解のための化合物 |
| WO2022051616A1 (en) * | 2020-09-03 | 2022-03-10 | Board Of Regents Of The University Of Nebraska | Cdk targeted heterobifunctional small molecule proteolysis targeting chimeras |
| CA3217417A1 (en) | 2021-05-05 | 2022-11-10 | Kevin M. Guckian | Compounds for targeting degradation of bruton's tyrosine kinase |
| CN113336801B (zh) * | 2021-06-08 | 2023-08-22 | 中国人民解放军空军军医大学 | 含有bet抑制剂的四价铂配合物与应用 |
| UY39844A (es) | 2021-07-07 | 2023-01-31 | Biogen Ma Inc | Compuestos para la degradación selectiva de las proteínas irak4 |
| JP2024525580A (ja) | 2021-07-07 | 2024-07-12 | バイオジェン・エムエイ・インコーポレイテッド | Ｉｒａｋ４タンパク質の分解をターゲティングするための化合物 |
| WO2024006776A1 (en) | 2022-06-27 | 2024-01-04 | Relay Therapeutics, Inc. | Estrogen receptor alpha degraders and medical use thereof |
| WO2024006781A1 (en) | 2022-06-27 | 2024-01-04 | Relay Therapeutics, Inc. | Estrogen receptor alpha degraders and use thereof |
| WO2024050016A1 (en) | 2022-08-31 | 2024-03-07 | Oerth Bio Llc | Compositions and methods for targeted inhibition and degradation of proteins in an insect cell |
| CN116585322B (zh) * | 2023-01-16 | 2023-10-13 | 中山大学中山眼科中心 | Bet蛋白降解剂在预防和治疗视网膜退行性改变相关疾病中的应用 |
| TW202500126A (zh) | 2023-05-24 | 2025-01-01 | 美商金橘生物科技公司 | 雜環化合物及其用途 |
| WO2025007000A1 (en) | 2023-06-30 | 2025-01-02 | Kumquat Biosciences Inc. | Substituted condensed tricyclic amine compounds and uses thereof as ras inhibitors |
| WO2025049555A1 (en) | 2023-08-31 | 2025-03-06 | Oerth Bio Llc | Compositions and methods for targeted inhibition and degradation of proteins in an insect cell |
| TW202523291A (zh) | 2023-11-02 | 2025-06-16 | 美商金橘生物科技公司 | 降解劑及其用途 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1982001011A1 (en) | 1980-09-24 | 1982-04-01 | Corp Cetus | Diagnostic method and probe |
| US4582788A (en) | 1982-01-22 | 1986-04-15 | Cetus Corporation | HLA typing method and cDNA probes used therein |
| EP0084796B1 (en) | 1982-01-22 | 1990-05-02 | Cetus Corporation | Hla typing method and cdna probes used therein |
| US4683194A (en) | 1984-05-29 | 1987-07-28 | Cetus Corporation | Method for detection of polymorphic restriction sites and nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| CA1284931C (en) | 1986-03-13 | 1991-06-18 | Henry A. Erlich | Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids |
| CA1338457C (en) | 1986-08-22 | 1996-07-16 | Henry A. Erlich | Purified thermostable enzyme |
| US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| PT989131E (pt) | 1996-09-13 | 2003-03-31 | Mitsubishi Pharma Corp | Compostos de trienotriazolodiazepina e suas utilizacoes com fins medicinais |
| US7091353B2 (en) * | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
| US20030045552A1 (en) * | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| FR2843126B1 (fr) | 2002-08-01 | 2006-01-27 | Cis Bio Int | "methode de determination d'une activite enzymatique endoglycosidase" |
| EP1887008B1 (en) | 2005-05-30 | 2021-04-21 | Mitsubishi Tanabe Pharma Corporation | Thienotriazolodiazepine compound and a medicinal use thereof |
| MX2009008099A (es) | 2007-02-01 | 2009-12-14 | Resverlogix Corp | Compuestos para la prevencion y tratamiento de enfermedades cardiovasculares. |
| EP2239264A4 (en) | 2007-12-28 | 2012-01-11 | Mitsubishi Tanabe Pharma Corp | ANTITUMORAL MEDIUM |
| KR101629356B1 (ko) | 2008-06-26 | 2016-06-13 | 리스버로직스 코퍼레이션 | 퀴나졸리논 유도체의 제조방법 |
| MX361467B (es) * | 2008-10-29 | 2018-12-06 | Celgene Corp | Compuestos de isoindolina para uso en el tratamiento de cancer. |
| DK2421533T3 (en) | 2009-04-22 | 2019-01-07 | Resverlogix Corp | Hitherto unknown anti-inflammatory agents |
| DE102009051823A1 (de) | 2009-11-04 | 2011-05-05 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Einkristallines Schweißen von direktional verfestigten Werkstoffen |
| GB0919426D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB0919432D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Use |
| KR20120097508A (ko) | 2009-11-05 | 2012-09-04 | 글락소스미스클라인 엘엘씨 | 벤조디아제핀 브로모도메인 억제제 |
| GB0919434D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB0919423D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| PL2536706T3 (pl) * | 2010-02-11 | 2017-10-31 | Celgene Corp | Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania |
| JP5913292B2 (ja) | 2010-05-14 | 2016-04-27 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | 代謝を調節する組成物および方法 |
| US8981083B2 (en) | 2010-05-14 | 2015-03-17 | Dana Farber Cancer Institute, Inc. | Compositions and methods for treating neoplasia, inflammatory disease and other disorders |
| MX373121B (es) | 2010-05-14 | 2020-04-30 | Dana Farber Cancer Inst Inc | Composiciones y metodos para el tratamiento de leucemia. |
| JO2998B1 (ar) * | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
| US9085582B2 (en) | 2010-06-22 | 2015-07-21 | Glaxosmithkline Llc | Benzotriazolodiazepine compounds inhibitors of bromodomains |
| AR084070A1 (es) | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
| US9249161B2 (en) | 2010-12-02 | 2016-02-02 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| EP2677865A4 (en) | 2011-02-23 | 2015-04-22 | Icahn School Med Mount Sinai | BROMODOMAIN INHIBITORS AS MODULATORS OF GENE EXPRESSION |
| WO2012151512A2 (en) | 2011-05-04 | 2012-11-08 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| US9328117B2 (en) | 2011-06-17 | 2016-05-03 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| GB201114103D0 (en) | 2011-08-17 | 2011-09-28 | Glaxosmithkline Llc | Novel compounds |
| WO2013027168A1 (en) | 2011-08-22 | 2013-02-28 | Pfizer Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
| WO2013033270A2 (en) | 2011-08-29 | 2013-03-07 | Coferon, Inc. | Bromodomain ligands capable of dimerizing in an aqueous solution, and methods of using same |
| DE102011082013A1 (de) | 2011-09-01 | 2013-03-07 | Bayer Pharma AG | 6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine |
| WO2013097052A1 (en) | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
| RU2666530C2 (ru) * | 2012-01-12 | 2018-09-11 | Йейл Юниверсити | Соединения и способы усиления деградации белков-мишеней и других полипептидов с помощью е3 убиквитин лигазы |
| US20140079636A1 (en) * | 2012-04-16 | 2014-03-20 | Dinesh U. Chimmanamada | Targeted therapeutics |
| US20130281399A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
| CA2870931A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Isoindolone derivatives |
| AU2012382373A1 (en) | 2012-06-12 | 2014-12-11 | Abbvie Inc. | Pyridinone and pyridazinone derivatives |
| WO2014134201A1 (en) * | 2013-02-28 | 2014-09-04 | Amgen Inc. | A benzoic acid derivative mdm2 inhibitor for the treatment of cancer |
| EP2970312B1 (en) * | 2013-03-11 | 2017-11-15 | The Regents of The University of Michigan | Bet bromodomain inhibitors and therapeutic methods using the same |
| US9580430B2 (en) * | 2014-02-28 | 2017-02-28 | The Regents Of The University Of Michigan | 9H-pyrimido[4,5-B]indoles and related analogs as BET bromodomain inhibitors |
| US20160058872A1 (en) * | 2014-04-14 | 2016-03-03 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| JP6778114B2 (ja) * | 2014-04-14 | 2020-10-28 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | イミド系タンパク質分解モジュレーター及び関連する使用方法 |
| WO2016138332A1 (en) * | 2015-02-27 | 2016-09-01 | The Regents Of The University Of Michigan | 9h-pyrimido [4,5-b] indoles as bet bromodomain inhibitors |
| WO2017030814A1 (en) * | 2015-08-19 | 2017-02-23 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| AU2017246453A1 (en) * | 2016-04-06 | 2018-11-08 | The Regents Of The University Of Michigan | Monofunctional intermediates for ligand-dependent target protein degradation |
-
2017
- 2017-04-06 BR BR112018070859A patent/BR112018070859A2/pt not_active IP Right Cessation
- 2017-04-06 KR KR1020187032621A patent/KR20180132861A/ko not_active Abandoned
- 2017-04-06 MX MX2018012379A patent/MX384905B/es unknown
- 2017-04-06 JP JP2018553365A patent/JP7072519B2/ja not_active Expired - Fee Related
- 2017-04-06 EP EP17717993.4A patent/EP3442976B1/en active Active
- 2017-04-06 CN CN201780036434.9A patent/CN109311890B/zh not_active Expired - Fee Related
- 2017-04-06 RU RU2018139537A patent/RU2752677C2/ru active
- 2017-04-06 US US16/093,160 patent/US10633386B2/en active Active
- 2017-04-06 UA UAA201811059A patent/UA123168C2/uk unknown
- 2017-04-06 SG SG11201808729WA patent/SG11201808729WA/en unknown
- 2017-04-06 WO PCT/US2017/026278 patent/WO2017180417A1/en not_active Ceased
- 2017-04-06 CA CA3020541A patent/CA3020541A1/en active Pending
- 2017-04-06 AU AU2017250076A patent/AU2017250076B2/en not_active Ceased
-
2018
- 2018-10-04 IL IL262139A patent/IL262139B/en active IP Right Grant
- 2018-10-18 ZA ZA2018/06969A patent/ZA201806969B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017250076A1 (en) | 2018-11-08 |
| UA123168C2 (uk) | 2021-02-24 |
| BR112018070859A2 (pt) | 2019-02-05 |
| CN109311890B (zh) | 2021-08-31 |
| JP7072519B2 (ja) | 2022-05-20 |
| RU2018139537A (ru) | 2020-05-14 |
| RU2752677C2 (ru) | 2021-07-29 |
| AU2017250076B2 (en) | 2021-07-22 |
| SG11201808729WA (en) | 2018-11-29 |
| KR20180132861A (ko) | 2018-12-12 |
| IL262139A (en) | 2018-11-29 |
| EP3442976B1 (en) | 2022-07-20 |
| ZA201806969B (en) | 2019-12-18 |
| CA3020541A1 (en) | 2017-10-19 |
| EP3442976A1 (en) | 2019-02-20 |
| US10633386B2 (en) | 2020-04-28 |
| IL262139B (en) | 2021-05-31 |
| RU2018139537A3 (enExample) | 2020-08-11 |
| JP2019511528A (ja) | 2019-04-25 |
| CN109311890A (zh) | 2019-02-05 |
| MX2018012379A (es) | 2019-07-04 |
| US20190169195A1 (en) | 2019-06-06 |
| WO2017180417A1 (en) | 2017-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX384905B (es) | Degradadores de proteínas de bromodominio y dominioextraterminal (bet). | |
| PH12019501321B1 (en) | Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders | |
| WO2017176957A8 (en) | Mdm2 protein degraders | |
| MX381588B (es) | N-(fenilsulfonil)benzamidas y compuestos relacionados como inhibidores de bcl-2. | |
| MX2023006257A (es) | Inhibidores de smyd. | |
| MX384087B (es) | Piperidinas como inhibidores de menina. | |
| PH12018500041A1 (en) | Substituted aza compoounds as irak-4 inhibitors | |
| PH12018500040A1 (en) | Indazole and azaindazole compounds as irak-4 inhibitors | |
| MX2021006011A (es) | Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma. | |
| MX2017002986A (es) | Compuestos de piperidina sustituidos. | |
| MX2020012165A (es) | Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cancer. | |
| PH12016502382A1 (en) | Substituted indazole compounds as irak4 inhibitors | |
| BR112015029495A2 (pt) | compostos heterocíclicos como inibidores da via de sinalização hedgehog | |
| MX380928B (es) | Inhibidores de kras g12c. | |
| MX2015009270A (es) | Pirazoles sustituidos en posicion 3 y uso de los mismos como inhibidores de la cinasa cremallera de leucinas dual (dlk). | |
| WO2015100092A3 (en) | 7-beta analogs of orvinols | |
| PH12016502353A1 (en) | Pharmaceutical composition | |
| TW201613577A (en) | Pharmaceutical combinations | |
| MX394245B (es) | Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia. | |
| EA201491227A1 (ru) | Новые производные морфолинила, подходящие для применения в качестве ингибиторов mogat-2 | |
| AU2017394032A8 (en) | Use of paeoniflorin-6'-o-benzenesulfonate in treatment of sjögren's syndrome | |
| PH12017501214A1 (en) | Cgrp antagonist peptides | |
| PH12016502480A1 (en) | Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases | |
| WO2019040104A3 (en) | COMPOUNDS, RELATED SALTS AND METHODS OF TREATING DISEASES | |
| TN2018000175A1 (en) | Indane derivatives as mglur7 modulators |